Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURE phase III trial of subcutaneous AIN457 versus placebo in active non-infectious intermediate, posterior, or panuveitis
2009-014834-22Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more (4 arms), sponsored by Novartis. Primary endpoint: Induction and maintenance of uveitis quiescence. Started Mar 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on 2009-014834-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014834-22.